```
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *


FILE 'HOME' ENTERED AT 19:07:44 ON 18 OCT 2007

=>  file medline embase biosis sciscearch caplus
'SCISCEARCH' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):sciscearch
'SCISCEARCH' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):ignore
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'MEDLINE' ENTERED AT 19:08:31 ON 18 OCT 2007

FILE 'EMBASE' ENTERED AT 19:08:31 ON 18 OCT 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 19:08:31 ON 18 OCT 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 19:08:31 ON 18 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> file scisearch
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       3.26       3.47

FILE 'SCISEARCH' ENTERED AT 19:08:51 ON 18 OCT 2007
Copyright (c) 2007 The Thomson Corporation


FILE COVERS 1974 TO 11 Oct 2007 (20071011/ED)

SCISEARCH has been reloaded, see HELP RLOAD for details.

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
```

	ENTRY	SESSION
FULL ESTIMATED COST	2.61	6.08

STN INTERNATIONAL LOGOFF AT 19:09:15 ON 18 OCT 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSSPTA1644PNH

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 02	LMEDLINE coverage updated
NEWS 3	JUL 02	SCISEARCH enhanced with complete author names
NEWS 4	JUL 02	CHEMCATS accession numbers revised
NEWS 5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 6	JUL 16	CAplus enhanced with French and German abstracts
NEWS 7	JUL 18	CA/CAplus patent coverage enhanced
NEWS 8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9	JUL 30	USGENE now available on STN
NEWS 10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 11	AUG 06	BEILSTEIN updated with new compounds
NEWS 12	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 13	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 14	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 15	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 16	AUG 27	USPATOLD now available on STN
NEWS 17	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 18	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 19	SEP 13	FORIS renamed to SOFIS
NEWS 20	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 21	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 22	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 23	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 24	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

```
  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *


FILE 'HOME' ENTERED AT 19:09:34 ON 18 OCT 2007

=> file medline embase biosis scisearch caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'MEDLINE' ENTERED AT 19:09:49 ON 18 OCT 2007

FILE 'EMBASE' ENTERED AT 19:09:49 ON 18 OCT 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 19:09:49 ON 18 OCT 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 19:09:49 ON 18 OCT 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 19:09:49 ON 18 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s KDR
L1         9883 KDR

=> s l1 or Flk-1 or VEGFR-2
L2        18983 L1 OR FLK-1 OR VEGFR-2

=> s l2 and peptide
L3         1160 L2 AND PEPTIDE

=> s l3 and HLA
L4           26 L3 AND HLA

=> dup remove l4
PROCESSING COMPLETED FOR L4
L5           22 DUP REMOVE L4 (4 DUPLICATES REMOVED)

=> s l5 and pd<20030307
   1 FILES SEARCHED...
   4 FILES SEARCHED...
L6            4 L5 AND PD<20030307

=> d l6 1-4 cbib abs

L6   ANSWER 1 OF 4     MEDLINE on STN
2001321766.    PubMed ID: 11211940.   Dendritic cells derived from peripheral
     monocytes express endothelial markers and in the presence of angiogenic
     growth factors differentiate into endothelial-like cells. Fernandez Pujol
     B; Lucibello F C; Zuzarte M; Lutjens P; Muller R; Havemann K. (Institute
     of Molecular Biology and Tumor Research, University of Marburg, Germany. )
     European journal of cell biology, (2001 Jan) Vol. 80, No. 1, pp.
     99-110.  Journal code: 7906240. ISSN: 0171-9335. Pub. country: Germany:
     Germany, Federal Republic of. Language: English.
AB   CD14-positive monocytes obtained from human peripheral blood were cultured
```

with GM-CSF and IL-4. During the early culture phase immature dendritic cells (DCs) developed which not only expressed CD1a, **HLA**-DR and CD86, but also expressed the endothelial cell markers von Willebrand factor (vWF), VE-cadherin and VEGF receptors Flt-1 and Flt-4. Further maturation of DCs was achieved by prolonged cultivation with TNFalpha. These cells showed typical DC morphology and like professional antigen-presenting cells (APCs) expressed CD83 and high levels of **HLA**-DR and CD86. However, if immature DCs were grown with VEGF, bFGF and IGF-1 on fibronectin/vitronectin-coated culture dishes, a marked change in morphology into caudated or oval cells occurred. In the presence of these angiogenic growth factors the cultured cells developed into endothelial-like cells (ELCs), characterized by increased expression of vWF, **KDR** and Flt-4 and a disappearance of CD1a and CD83. Addition of IL-4 and Oncostatin M also increased VE-cadherin expression, and the loosely adherent cells formed clusters, cobblestones and network-like structures. vWF- expressing ELCs mainly originated from CD1a-positive cells, and VEGF was responsible for the decrease in the expression of the DC markers CD1a and CD83. In mixed leukocyte cultures, mature DCs were more potent APCs than ELCs. Moreover, Ac-LDL uptake, and the formation of tubular structures on a plasma matrix was restricted to ELCs. These results suggest that in the presence of specific cytokines immature DCs have the potential to differentiate along different lineages, i.e. into a cell type resembling ELCs.

L6 ANSWER 2 OF 4 MEDLINE on STN

1999300696. PubMed ID: 10372108. Expression of novel surface antigens on early hematopoietic cells. Buhring H J; Seiffert M; Bock T A; Scheding S; Thiel A; Scheffold A; Kanz L; Brugger W. (Department of Hematology and Oncology, University of Tubingen, Germany.. hjbuehri@med.uni-tuebingen.de) . Annals of the New York Academy of Sciences, **(1999 Apr 30)** Vol. 872, pp. 25-38; discussion 38-9. Journal code: 7506858. ISSN: 0077-8923. Pub. country: United States. Language: English.

AB The purpose of this report is to demonstrate the expression of very recently identified surface antigens on CD34+ and AC133+ bone marrow (BM) cells. Coexpression analysis of AC133 and defined antigens on CD34+ BM cells revealed that the majority of the CD164+, CD135+, CD117+, CD38low, CD33+, and CD71low cells resides in the AC133+ population. In contrast, most of the CD10+ and CD19+ B cell progenitors and a fraction of the CD71high population are AC133-, indicating that CD34+AC133+ cells are enriched in primitive and myeloid progenitor cells, whereas CD34+AC133- cells mainly consist of B cell and late erythroid progenitors.. This corresponds to the highly reduced percentage of CD10+ B cells and the absence of CD71high erythroid progenitors on AC133+ selected BM cells. A portion of 0.2-0.7% of the AC133+ selected cells do not coexpress CD34. These cells are very small and define a uniform CD71-, CD117-, CD10-, CD38low, CD135+, **HLA**-DRhigh, CD45+ population with unknown delineation. Four color analysis on CD34+CD38- BM cells revealed that virtually all of these primitive cells express AC133. Using an improved liposome-enhanced labeling technique for the staining of weakly expressed antigens, subsets of this population could be identified which express the angiopoietin receptors TIE (67.6%) and TEK (36.8%), the vascular endothelial growth factor receptors FLT1 (7%), FLT4 (3.2%), and **KDR** (10.4%), or the receptor tyrosine kinases HER-2 (15.4%) and FLT3 (CD135; 77.6%). Our results suggest that the CD34+CD38- population is heterogeneous with respect to the expression of the analyzed receptor tyrosine kinases.

L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

2007:621423 Document No. 147:16719 Progenitor endothelial cell capturing with a drug eluting implantable medical device. Cottone, Robert John, Jr.; Rowland, Stephen M.; Parker, Sherry (Orbusneich Medical, Inc., USA). U.S. Pat. Appl. Publ. US 2007128723 A1 20070607, 47 pp., Cont..-in-part of U.S. Ser. No. 76,731. (English). CODEN: USXXCO. APPLICATION: US 2006-560352 20061115. PRIORITY: US 2005-76731 20050310; US 2003-442669 20030520; US 2003-360567 20030206; US 2001-808867 20010315; US

2006-822451P 20060815; US 2005-736920P 20051115; US 2002-382095P 20020520; US 2002-354680P 20020206; US 2000-201789P 20000504; US 2000-189674P 20000315.

AB A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates pos. blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a **peptide**, an antibody or a small mol. for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

L6 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

2003:971783 Document No. 140:19916 Medical device with coating that promotes cell adherence and differentiation. Kutryk, Michael J. B.; Cottone, Robert J., Jr.; Rowland, Stephen M.; Kuliszewski, Michael A. (Can.). U.S. Pat. Appl. Publ. US 2003229393 A1 20031211, 41 pp., Cont.-in-part of U.S. Ser. No. 808,867. (English). CODEN: USXXCO. APPLICATION: US 2003-360567 20030206. PRIORITY: US 2001-808867 20010315; US 2002-354680P 20020206.

AB Compns. and methods are provided for producing a medical device such as a stent, a stent graft, a synthetic vascular graft, heart valves, coated with a biocompatible matrix which incorporates antibodies, antibody fragments, or small mols., which recognize, bind to and/or interact with a progenitor cell surface antigen to immobilize the cells at the surface of the device. The coating on the device can also contain a compound or growth factor for promoting the progenitor endothelial cell to accelerate adherence, growth and differentiation of the bound cells into mature and functional endothelial cells on the surface of the device to prevent intimal hyperplasia. Methods for preparing such medical devices, compns., and methods for treating a mammal with vascular disease such as restenosis, atherosclerosis or other types of vessel obstructions are disclosed. CMDX-coated stainless steel samples having anti-CD34 antibody bound on its surface. The samples contained numerous adherent cell near confluent monolayer.

```
=> s "VYSSEEAEL"
L7            0 "VYSSEEAEL"

=> s l1 and GYRIYDVVL
L8            0 L1 AND GYRIYDVVL

=> d his

     (FILE 'HOME' ENTERED AT 19:09:34 ON 18 OCT 2007)

     FILE 'MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS' ENTERED AT 19:09:49 ON
     18 OCT 2007
L1         9883 S KDR
L2        18983 S L1 OR FLK-1 OR VEGFR-2
L3         1160 S L2 AND PEPTIDE
L4           26 S L3 AND HLA
L5           22 DUP REMOVE L4 (4 DUPLICATES REMOVED)
L6            4 S L5 AND PD<20030307
L7            0 S "VYSSEEAEL"
L8            0 S L1 AND GYRIYDVVL

=> s l3 and "SYMISYAGM"
L9            0 L3 AND "SYMISYAGM"

=> s l3 and "RFVPDGNRI"
L10           0 L3 AND "RFVPDGNRI"
```

```
=> s "KWEFPRDRL"
L11           0 "KWEFPRDRL"

=> s "DFLTLEHLI"
L12           0 "DFLTLEHLI"

=> s "AMFFWLLLV"
L13           0 "AMFFWLLLV"

=> s "VIAMFFWLL"
L14           0 "VIAMFFWLL"

=> s "AVIAMFFWL"
L15           0 "AVIAMFFWL"

=> s "KLIEIGVQT"
L16           0 "KLIEIGVQT"

=> s "YMISYAGMV"
L17           0 "YMISYAGMV"

=> s "IQSDVWSFGV"
L18           0 "IQSDVWSFGV"

=> s human vascular growth factor receptor 2
L19           0 HUMAN VASCULAR GROWTH FACTOR RECEPTOR 2

=> s "human VEGFR2"
L20          55 "HUMAN VEGFR2"

=> s l20 and CTL epitope
L21           0 L20 AND CTL EPITOPE

=> s l20 and HLA
L22           0 L20 AND HLA

=> s l20 and peptide
L23           2 L20 AND PEPTIDE

=> dup remove l23
PROCESSING COMPLETED FOR L23
L24           2 DUP REMOVE L23 (0 DUPLICATES REMOVED)

=> d l24 1-2 cbib abs

L24  ANSWER 1 OF 2     MEDLINE on STN
2004284100.    PubMed ID: 15183093.   Human/mouse cross-reactive anti-VEGF
     receptor 2 recombinant antibodies selected from an immune b9 allotype
     rabbit antibody library. Popkov Mikhail; Jendreyko Nina; Gonzalez-Sapienza
     Gualberto; Mage Rose G; Rader Christoph; Barbas Carlos F 3rd. (Department
     of Molecular Biology, The Scripps Research Institute, La Jolla, CA 92037,
     USA. ) Journal of immunological methods, (2004 May) Vol. 288, No. 1-2, pp.
     149-64.  Journal code: 1305440. ISSN: 0022-1759. Pub. country:
     Netherlands. Language: English.
AB   Vascular endothelial growth factor (VEGF) and its receptors have been
     implicated in promoting solid tumor growth and metastasis via stimulating
     tumor-associated angiogenesis.  Models of murine tumor angiogenesis and
     receptor-specific antibodies are required to evaluate roles of VEGF
     receptors in mouse models of human cancer.  Human VEGFR2
     (also known as KDR) and murine VEGFR2 (or Flk-1) share 85% amino acid
     sequence identity in their extracellular domain.  We describe here the
     development of antibodies that cross-react with mouse and human
     VEGFR2.  High-affinity, species cross-reactive, Fabs specific for
     KDR/Flk-1 were selected from an antibody phage display library generated
```

from an immunized rabbit of b9 allotype. The selected chimeric rabbit/human Fabs were found to bind to purified KDR and Flk-1 with nanomolar affinity. Three of the selected Fabs detected KDR expression on human endothelial cells as well as Flk-1 on murine endothelial cells. The availability of anti-VEGFR2 Fab with species cross-reactivity will help to decipher the functional role of KDR/Flk-1 in tumor biology as well as facilitate the preclinical evaluation of the suitability of KDR/Flk-1 for drug targeting. This report underscores our earlier finding that b9 rabbits are excellent sources for high-affinity cross-reactive antibodies with therapeutic potential.

L24 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
2003:850821 Document No. 140:92257 Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. Lu, Dan; Shen, Juqun; Vil, Marie D.; Zhang, Haifan; Jimenez, Xenia; Bohlen, Peter; Witte, Larry; Zhu, Zhenping (Department of Antibody Technology, ImClone Systems Incorporated, New York, NY, 10014, USA). Journal of Biological Chemistry, 278(44), 43496-43507 (English) 2003. CODEN: JBCHA3. ISSN: 0021-9258. Publisher: American Society for Biochemistry and Molecular Biology.

AB Vascular endothelial growth factor (VEGF) and its receptors have been implicated in promoting solid tumor growth and metastasis via stimulating tumor-associated angiogenesis. We previously identified several fully human neutralizing anti-VEGF receptor 2 (or kinase inserting domain-containing receptor (KDR)) antibodies from a large antibody phage display library. These antibodies bind specifically to KDR, block VEGF/KDR interaction, and inhibit VEGF-induced proliferation of human endothelial cells and migration of KDR+ leukemia cells. Three of these antibodies, interestingly, share an identical heavy chain variable (VH) sequence. In this report, we constructed a new library comprising the single VH paired with the variable light chain (VL) repertoire obtained from the original naive human library. Initial in vitro selection revealed that the single VH could pair with a number of different VL while retaining its specificity for KDR. However, a consensus VH/VL pair, clone 1121, was identified after three or four rounds of selection by tailoring the stringency of the panning conditions. Clone 1121 showed a >30-fold higher binding affinity to KDR (Kd, 100 pM) because of improvement on both association and dissociation consts. and blocked VEGF/KDR interaction with an IC50 of .apprx.1 nM, compared with that of 3-4 nM for the parent Fab fragments. Further, clone 1121 was more potent in inhibiting VEGF-stimulated KDR phosphorylation in endothelial cells. A binding epitope mapping study on clone 1121 and one of the parent clones, 2C6, demonstrated that both antibodies interacted with the third Ig domain within the extracellular region of KDR. Several **peptide** phage display libraries were utilized to further examine the fine binding specificities of the two antibodies. All of the 2C6-binding **peptides** are cysteine-constrained, whereas clone 1121 binds to both cysteine-constrained and linear **peptides.** It is noteworthy that most of the 2C6-binding **peptides** also cross-react with clone 1121, but none of the clone 1121-specific **peptides** binds to 2C6, indicating that clone 1121 retained part of the original binding epitope(s) of 2C6 while gaining new binding specificity. Taken together, our observation suggests that clone 1121 may have great clin. potential in anti-angiogenesis therapy. It further underscores the efforts to identify antibodies of high affinity for enhanced biol. activities.

```
=> s CTL epitope
L25        6703 CTL EPITOPE

=> s l25 and KDR
L26           1 L25 AND KDR
```

=> d l26 cbib abs

L26 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
2000:240985 Document No. 132:292701 Novel methods for therapeutic vaccination. Steinaa, Lucilla; Mouritsen, Soren; Nielsen, Klaus Gregorious; Haaning, Jesper; Leach, Dana; Dalum, Iben; Gautam, Anand; Birk, Peter; Karlsson, Gunilla (M & E Biotech A/S, Den.). PCT Int. Appl. WO 2000020027 A2 20000413, 220 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-DK525 19991005. PRIORITY: DK 1998-1261 19981005; US 1998-PV105011 19981020.

AB A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one **CTL epitope** of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. prostate specific membrane antigen (PSM), Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogs of PSM, Her2 and FGF8b, as well as nucleic acid mols. encoding these analogs. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogs of weak or non-immunogenic antigens.

=> s l25 and VEGFR2
L27 0 L25 AND VEGFR2

=> s l25 and FLK-1
L28 0 L25 AND FLK-1

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	100.49	100.70

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.12	-3.12

STN INTERNATIONAL LOGOFF AT 19:16:31 ON 18 OCT 2007